Baxter to pay $4bn for dialysis firm


US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion (£2.5 billion)

‘Baxter has a legacy of innovation in dialysis, including the development of peritoneal dialysis for the treatment of end-stage kidney disease patients in the home,’ said Baxter chief executive Robert Parkinson. ‘This acquisition further strengthens our global dialysis offerings by extending our portfolio in the haemodialysis segment.’

Gambro, which is based in Lund, makes products for haemodialysis and continuous renal replacement therapy, generating annual sales of $1.6 billion in 2011.

According to Baxter, more than two million people are undergoing to some form of ongoing dialysis treatment, with dialysis treatment rates increasing more than 5% annually, in part as a result of rising rates of diabetes and hypertension. The company says that healthcare providers are seeking comprehensive dialysis treatment options that vary by region, in order to serve patients based on clinical need, existing infrastructure and reimbursement policy.


Related Content

Baxter aims to divide and conquer

28 March 2014 Business

news image

Firm will split off its biopharmaceuticals business from medical products

10 years ago - Alain Baxter

1 May 2012 Flashback

news image

British Olympic skier Alain Baxter had his bronze medal taken away after a post-race drug test showed traces of methamphetami...

Most Read

Coated nanoparticles show Alzheimer's promise

12 September 2014 News and Analysis

news image

Gold nanoparticles functionalised with amino acid polymer inhibit the growth of amyloid fibres associated with neurodegenerat...

Computer simulations point to formamide as prebiotic intermediate in ‘Miller’ mixtures

16 September 2014 News and Analysis

news image

Electric field may have provided more than just energy for primordial chemistry

Most Commented

US genomics lead being lost to China

17 September 2014 News and Analysis

news image

NIH senior leaders are sounding the alarm bells, saying the US's pre-eminence in genomics research is under threat

The trouble with boycotts

29 August 2014 Critical Point

news image

Cutting academic ties with a censured state can do more harm than good, says Mark Peplow